
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 2, Issue 12 2029-2035, Copyright © 1996 by American Association for Cancer Research
ARTICLES |
W Park, JJ Choi, ES Hwang and JH Lee
Center for Clinical Research, Samsung Biomedical Research Institute, and Department of Obstetrics and Gynecology, Samsung Medical Center, 50 Ilwon-dong, Kangnam-ku, Seoul 135-230, Korea.
By means of reverse transcription-PCR we have identified an alternatively spliced mRNA coding for a variant estrogen receptor (ER) that lacks exon 4 (ERDelta4) and is coexpressed with the wild-type ER mRNA in ovarian carcinomas. Furthermore, Western blot analysis revealed the expression of the ERDelta4 protein in normal as well as neoplastic ovarian tissues along with the wild-type ER, although the relative amounts of the wild-type ER and ERDelta4 proteins varied. The trans-activational properties of this variant were studied in ER-negative COS1 cell lines by cotransfection of the ERDelta4 expression vector and a reporter gene containing the estrogen response element. The ERDelta4 protein was not able to activate transcription of a reporter gene. However, it inhibited estrogen-dependent transcriptional activation in a dominant negative fashion when it was cotransfected with the wild-type ER and reporter plasmid. Because it has been shown that ERDelta4 is not able to bind to its response element, the observed inhibitory effect probably occurs through protein-protein interactions. Although several variants of the ER have been described from cancerous cells, none has been identified in ovarian tissues, and ERDelta4 is the only isoform detected in normal tissues. These results may have implications for understanding the physiological role of ERDelta4 in normal cells, because it may affect the function of the wild-type ER, depending on the level of the variant ER protein relative to that of the wild-type ER.
This article has been cited by other articles:
![]() |
T. A. Ishunina, D. F. Swaab, and D. F. Fischer Estrogen Receptor-{alpha} Splice Variants in the Medial Mamillary Nucleus of Alzheimer's Disease Patients: Identification of a Novel MB1 Isoform J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3757 - 3765. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Herynk and S. A. W. Fuqua Estrogen Receptor Mutations in Human Disease Endocr. Rev., December 1, 2004; 25(6): 869 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Garcia Pedrero, P. Zuazua, C. Martinez-Campa, P. S. Lazo, and S. Ramos The Naturally Occurring Variant of Estrogen Receptor (ER) ER{Delta}E7 Suppresses Estrogen-Dependent Transcriptional Activation by Both Wild-Type ER{alpha} and ER{beta} Endocrinology, July 1, 2003; 144(7): 2967 - 2976. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Platet, S. Cunat, D. Chalbos, H. Rochefort, and M. Garcia Unliganded and Liganded Estrogen Receptors Protect against Cancer Invasion via Different Mechanisms Mol. Endocrinol., July 1, 2000; 14(7): 999 - 1009. [Abstract] [Full Text] |
||||
![]() |
K.-M. Lau, S. C. Mok, and S.-M. Ho Expression of human estrogen receptor-alpha and -beta , progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells PNAS, May 11, 1999; 96(10): 5722 - 5727. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Balleine, S. M. N. Hunt, and C. L. Clarke Coexpression of Alternatively Spliced Estrogen and Progesterone Receptor Transcripts in Human Breast Cancer J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1370 - 1377. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |